Adicet Bio
ACET
64 hedge funds and large institutions have $55.4M invested in Adicet Bio in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.04% more ownership
Funds ownership: 4.33% → 4.37% (+0.04%)
0% more funds holding
Funds holding: 64 → 64 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
33% less capital invested
Capital invested by funds: $82.3M → $55.4M (-$26.8M)
48% less call options, than puts
Call options by funds: $27K | Put options by funds: $52K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$217K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$206K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$191K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$145K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$372K |
| 2 |
Morgan Stanley
New York
|
-$308K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$264K |
| 4 |
Millennium Management
New York
|
-$170K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$153K |
ACET Hedge Fund Activity: Q4 2024 in Review
64 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2024, worth a combined $55.4M — down 33% from $82.3M a quarter earlier.
Fund positioning in ACET was balanced in Q4 2024: 7 funds opened new positions, 7 closed out, 16 added to existing stakes and 23 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $217K. The largest seller was Renaissance Technologies, cutting an estimated $372K.
- 64 institutional investors held Adicet Bio (ACET) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $55.4M of Adicet Bio stock for Q4 2024, down 33% quarter-over-quarter.
- 7 funds opened new Adicet Bio positions in Q4 2024 and 7 closed out, a net change of 0 holders.
- The largest Adicet Bio buyer in Q4 2024 was Squarepoint, an estimated $217K added.
- The largest Adicet Bio seller in Q4 2024 was Renaissance Technologies, an estimated $372K sold.
Based on aggregated 13F filings for Q4 2024.